Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trialMathias Rummel, Wolfram Brugger, N. Niederle et al.|The Lancet|2013Cited by 1.5k
Bendamustine Plus Rituximab Is Superior in Respect of Progression Free Survival and CR Rate When Compared to CHOP Plus Rituximab as First-Line Treatment of Patients with Advanced Follicular, Indolent, and Mantle Cell Lymphomas: Final Results of a Randomized Phase III Study of the StiL (Study Group Indolent Lymphomas, Germany).Mathias Rummel, Wolfram Brugger, N. Niederle et al.|Blood|2009Cited by 157
Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trialMathias Rummel, Juergen Barth, Ulrich Kaiser et al.|The Lancet Oncology|2015Cited by 155
Perioperative trastuzumab and pertuzumab in combination with FLOT versus FLOT alone for HER2-positive resectable esophagogastric adenocarcinoma: Final results of the PETRARCA multicenter randomized phase II trial of the AIO.Ralf‐Dieter Hofheinz, Salah‐Eddin Al‐Batran, Georg Martin Haag et al.|Journal of Clinical Oncology|2020Cited by 91
Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent lymphomas: Nine-year updated results from the StiL NHL1 study.Mathias Rummel, Wolfram Brugger, Georg Maschmeyer et al.|Journal of Clinical Oncology|2017Cited by 83